The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can help align a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of PML immune checkpoint inhibitors require individualized development, usually including multidimensional management of drug therapy, rehabilitation, regular follow-up, etc. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many formerly difficult-to-treat neurological disorders have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule of disease changes. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PML-associated immune checkpoint inhibitors. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.